Seeking Alpha

Xtandi competitor ARN-509 "still has many outstanding questions/hurdles," JPMorgan's Geoff...

Xtandi competitor ARN-509 "still has many outstanding questions/hurdles," JPMorgan's Geoff Meacham says, reiterating an Overweight rating on shares of Medivation (MDVN -9.3%) which are currently in a tailspin following JNJ's acquisition of Aragon (I, II). Meacham acknowledges that Aragon's cause (both from a legal and development perspective) will be helped by JNJ's substantial resources, but notes that early stage prostate cancer agents face "significant clinical, regulatory, and commercial hurdles."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector